These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 26872435)

  • 1. Serum pentraxin-3 and tumor necrosis factor-like weak inducer of apoptosis (TWEAK) predict severity of infections in acute decompensated cirrhotic patients.
    Fan WC; Huang CC; Yang YY; Lin A; Lee KC; Hsieh YC; Fung CP; Hsu HC; Hou MC; Lin HC
    J Microbiol Immunol Infect; 2017 Dec; 50(6):905-914. PubMed ID: 26872435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe periodontitis is linked with increased peripheral levels of sTWEAK and PTX3 in chronic migraineurs.
    Leira Y; Ameijeira P; Domínguez C; López-Arias E; Ávila-Gómez P; Pérez-Mato M; Sobrino T; Campos F; D'Aiuto F; Leira R; Blanco J
    Clin Oral Investig; 2020 Feb; 24(2):597-606. PubMed ID: 31111284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating levels of pentraxin-3 (PTX3) in patients with liver cirrhosis.
    Narciso-Schiavon JL; Pereira JG; Silva TE; Bansho ETO; Morato EF; Pinheiro JT; Muraro-Wildner L; Bazzo ML; Dantas-Corrêa EB; Schiavon LL
    Ann Hepatol; 2017; 16(5):780-787. PubMed ID: 28809733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes.
    Yilmaz MI; Sonmez A; Ortiz A; Saglam M; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Çakar M; Egido J; Altun B; Yenicesu M; Blanco-Colio LM; Carrero JJ
    Clin J Am Soc Nephrol; 2011 Apr; 6(4):785-92. PubMed ID: 21330486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.
    Yilmaz MI; Carrero JJ; Martín-Ventura JL; Sonmez A; Saglam M; Celik T; Yaman H; Yenicesu M; Eyileten T; Moreno JA; Egido J; Blanco-Colio LM
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1174-81. PubMed ID: 20430947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers of Necrotising Soft Tissue Infections Aspects of the Innate Immune Response.
    Hansen MB
    Dan Med J; 2017 Jul; 64(7):. PubMed ID: 28673381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum soluble TWEAK levels in severe traumatic brain injury and its prognostic significance.
    Tang B; Zhong Z; Qiu Z; Wu HP; Hu JY; Ma JP; Wu JP
    Clin Chim Acta; 2019 Aug; 495():227-232. PubMed ID: 31009601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH.
    Boga S; Koksal AR; Alkim H; Yilmaz Ozguven MB; Bayram M; Ergun M; Sisman G; Tekin Neijmann S; Alkim C
    Metab Syndr Relat Disord; 2015 Nov; 13(9):393-9. PubMed ID: 26367098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated levels of the long pentraxin 3 in paracetamol-induced human acute liver injury.
    Craig DG; Lee P; Pryde EA; Walker SW; Beckett GJ; Hayes PC; Simpson KJ
    Eur J Gastroenterol Hepatol; 2013 Mar; 25(3):359-67. PubMed ID: 23169308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentraxin 3, a Predicator for 28-Day Mortality in Patients With Septic Shock.
    Jie H; Li Y; Pu X; Ye J
    Am J Med Sci; 2017 Mar; 353(3):242-246. PubMed ID: 28262210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of soluble TNF-like weak inducer of apoptosis (sTWEAK) levels to predict preeclampsia in early weeks of pregnancy.
    Shahid S; Khalid E; Fatima SS; Khan GM
    Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():165-170. PubMed ID: 30708268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated levels of systemic pentraxin 3 are associated with thin-cap fibroatheroma in coronary culprit lesions: assessment by optical coherence tomography and intravascular ultrasound.
    Koga S; Ikeda S; Yoshida T; Nakata T; Takeno M; Masuda N; Koide Y; Kawano H; Maemura K
    JACC Cardiovasc Interv; 2013 Sep; 6(9):945-54. PubMed ID: 23954061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Source of Circulating Pentraxin 3 in Septic Shock Patients.
    Albert Vega C; Mommert M; Boccard M; Rimmelé T; Venet F; Pachot A; Leray V; Monneret G; Delwarde B; Brengel-Pesce K; Mallet F; Trouillet-Assant S
    Front Immunol; 2018; 9():3048. PubMed ID: 30687307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality.
    Mauri T; Bellani G; Patroniti N; Coppadoro A; Peri G; Cuccovillo I; Cugno M; Iapichino G; Gattinoni L; Pesenti A; Mantovani A
    Intensive Care Med; 2010 Apr; 36(4):621-9. PubMed ID: 20119647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease.
    Fernández-Laso V; Méndez-Barbero N; Valdivielso JM; Betriu A; Fernández E; Egido J; Martín-Ventura JL; Blanco-Colio LM
    Atherosclerosis; 2017 May; 260():130-137. PubMed ID: 28390291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased circulating endocan in patients with cirrhosis: relation to bacterial infection and severity of disease.
    Zuwala-Jagiello J; Simon K; Kukla M; Murawska-Cialowicz E; Gorka-Dynysiewicz J; Grzebyk E; Pazgan-Simon M
    J Physiol Pharmacol; 2017 Apr; 68(2):273-282. PubMed ID: 28614777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease.
    Bozic M; Méndez-Barbero N; Gutiérrez-Muñoz C; Betriu A; Egido J; Fernández E; Martín-Ventura JL; Valdivielso JM; Blanco-Colio LM;
    Atherosclerosis; 2018 Mar; 270():13-20. PubMed ID: 29407881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients.
    Carrero JJ; Ortiz A; Qureshi AR; Martín-Ventura JL; Bárány P; Heimbürger O; Marrón B; Metry G; Snaedal S; Lindholm B; Egido J; Stenvinkel P; Blanco-Colio LM
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):110-8. PubMed ID: 18945991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions.
    Song J; Park DW; Moon S; Cho HJ; Park JH; Seok H; Choi WS
    BMC Infect Dis; 2019 Nov; 19(1):968. PubMed ID: 31718563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune dysfunction in cirrhosis: Distinct cytokines phenotypes according to cirrhosis severity.
    Dirchwolf M; Podhorzer A; Marino M; Shulman C; Cartier M; Zunino M; Paz S; Muñoz A; Bocassi A; Gimenez J; Di Pietro L; Romero G; Fainboim H; Fainboim L
    Cytokine; 2016 Jan; 77():14-25. PubMed ID: 26517154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.